Back
Full-text
Journal article

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer.

  • Wujanto C Department of Radiation Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singapore.
  • Vellayappan B Department of Radiation Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singapore.
  • Siva S Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Louie AV Department of Radiation Oncology, Sunnybrook Health Sciences Centre, The University of Toronto, Toronto, ON, Canada.
  • Guckenberger M Department for Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
  • Slotman BJ Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Onishi H Department of Radiology, University of Yamanashi, Kofu, Japan.
  • Nagata Y Department of Radiation Oncology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
  • Liu M Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada.
  • Lo SS Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Show more…
  • 2019-12-05
Published in:
  • Frontiers in oncology. - 2019
lung cancer
non-small cell lung cancer
oligometastases
oligometastatic disease
stereotactic body radiotherapy
English Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated with palliative intent platinum-based chemotherapy alone. Recent advances in imaging and therapeutic strategy have identified a subset of patients with limited metastases who may benefit from early local ablative therapy with either surgery or radiotherapy, in addition to standard treatment. Stereotactic body radiotherapy (SBRT) is increasingly used in the treatment of extra-cranial oligometastatic NSCLC (OM-NSCLC) due its non-invasive conduct and ability to deliver high doses. Clinical evidence supporting the use of SBRT in OM-NSCLC is emerging and consistently demonstrates significant benefit in local control and progression-free survival. Here, we discuss the definition of oligometastases (OM), review current available data on SBRT treatment in extra-cranial OM-NSCLC including evidence for site-specific SBRT in lung, liver, and adrenal metastases.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/236981
Statistics
Document views: 29 File downloads:
  • Full-text: 0